Enliven Therapeutics (NASDAQ: ELVN) — Perfil da empresa, notícias e dados financeiros
Enliven Therapeutics focuses on personalized cancer treatments, developing therapies that target specific pathways to improve outcomes.
Enliven Therapeutics
Enliven Therapeutics (NASDAQ:ELVN) focuses on innovative cancer treatments, emphasizing personalized medicine to optimize patient outcomes. At the core of its operations, Enliven Therapeutics merges cutting-edge research with advanced technology to develop therapies that target specific cancer pathways. The company's projects range from early-stage research to clinical trials, always aiming to bring novel solutions to the forefront of oncology care. Their objectives include revolutionizing cancer treatment through the discovery, development, and commercialization of therapies that offer improved efficacy and safety, ultimately striving to enhance the quality of life for patients battling cancer.
Resumo
Operações
Produtos e/ou serviços de Enliven Therapeutics
- Development of targeted cancer therapies focusing on genetically defined patient populations for precision medicine.
- Advancement of novel inhibitors for the treatment of lung cancer and other solid tumors.
- Research on immune system modulators to enhance the efficacy of existing cancer treatments.
- Collaboration with biotech and pharmaceutical companies to accelerate the development and commercialization of promising cancer therapies.
- Investment in cutting-edge technology to improve the delivery and specificity of oncology drugs.
- Initiation of clinical trials for new molecules with potential application across a range of cancers.
equipe executiva do Enliven Therapeutics
- Richard A. FairCEO, President & Director
- Samuel S. KintzCo-Founder & Head of Pipeline
- Benjamin HohlCFO & Head of Corporate Development
- Helen Louise CollinsChief Medical Officer
- Joseph P. LyssikatosCo-Founder & Research Fellow
- Anish PatelCo-Founder & COO
- Galya D. BlachmanChief Legal Officer & Head of Business Development
- Damiette SmitVice President of Clinical Development
Principais indicadores financeiros
Resultados divulgados pela Enliven Therapeutics, em USD.
- Cap. de mercado
- 3,3 bi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -119,7 mi | -103,7 mi | |
| 0 | -104,6 mi | -89 mi | |
| 0 | -83,5 mi | -71,6 mi | |
| 0 | -38,8 mi | -37,7 mi |